Integra LifeSciences Holdings (Nasdaq: IART) is expected to report Q3 earnings on Oct. 24. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Integra LifeSciences Holdings's revenues will grow 4.6% and EPS will wither 0.0%.

The average estimate for revenue is $211.4 million. On the bottom line, the average EPS estimate is $0.77.

Revenue details
 Last quarter, Integra LifeSciences Holdings tallied revenue of $210.2 million. GAAP reported sales were 8.7% higher than the prior-year quarter's $193.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.74. GAAP EPS of $0.30 for Q2 were much higher than the prior-year quarter's $0.02 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 64.5%, 40 basis points better than the prior-year quarter. Operating margin was 13.0%, 170 basis points worse than the prior-year quarter. Net margin was 4.1%, 370 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $834.5 million. The average EPS estimate is $3.04.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 158 members out of 170 rating the stock outperform, and 12 members rating it underperform. Among 54 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 53 give Integra LifeSciences Holdings a green thumbs-up, and one give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $42.31.